<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/">
<rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6988">
    <dcterms:title><![CDATA[<strong>Broadening the chemical diversity of oxidovanadium(V) complexes for targeting neglected tropical diseases</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[OXIDOVANADIO]]></dcterms:subject>
    <dcterms:subject><![CDATA[TRYPANOSOMA CRUZI]]></dcterms:subject>
    <dcterms:subject><![CDATA[LEISHMANIASIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[TRIPANOSOMIASIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ENFERMEDAD DE CHAGAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[LEISHMANIA INFANTUM]]></dcterms:subject>
    <dcterms:subject><![CDATA[8-HIDROXIQUINOLEINA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2025]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Chagas disease and Leishmaniasis, caused by Trypanosoma cruzi and Leishmania spp., respectively, are highly prevalent neglected tropical diseases (NTDs) that pose significant global health challenges. In our pursuit of effective vanadium-based therapeutics against these diseases, we previously developed several series of oxidovanadium( V) complexes featuring bidentate bioactive ligands and Schiff base tridentate ligands. The current study extends our previous research by incorporating in the same molecule, a tridentate bromo-substituted isonicotinyl hydrazone Schiff base ligand, BrIS, and a 8-hydroxyquinoline derivative (L), leading to the synthesis and comprehensive characterization of five new complexes, [VVO(BrIS-2H)(L-H)]. Most of new complexes exhibited activity in the micromolar range against the infective trypomastigote form of T. cruzi (EC50, 24h: 0.73–7.95 μM) and against L. infantum promastigotes (IC50, 5 days: 1.14–1.16 μM) and some of them showed good selectivity indexes towards the parasites (SI up to 52). Notably, the vanadium uptake by the parasites was higher for the new [VVO(BrIS-2H)(L-H)] compounds compared to [VVO(IN-2H)(L-H)] analogues previously developed, where IN is the structurally related 2-hydroxy-1-naphtaldehyde isonicotinoylhydrazone ligand, with accumulation in the soluble cell fraction. High-dose incubations resulted in trypanocidal effects and suggested the generation of reactive oxygen species (ROS). Further analysis revealed that [VVO(BrIS-2H)(L-H)] complexes induced a higher percentage of apoptosis, whereas the [VVO(IN-2H)(L-H)] series was associated with autophagic cell death. These findings highlight the potential of the [VVO(BrIS-2H)(L-H)] series as promising anti-T. cruzi agents and underscore the need for further research to optimize their therapeutic efficacy and explore their mechanisms of action.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?30f70e9dfd00c43ffab403face2bbb4fd0f8853410743d6fa48798782e4078d5bf0735c77ca026b5828f7194ff3401bbfd4bd422c0ea61fda7a3ceb0a5af09f8"><strong>Scalese, Gonzalo</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?39747faf0052cf8939cc3459d61fe58def8ff434943c72130f482c3eeb7fe307d8f436f1ee567bc92db0ed97be4ffcb554a3c9537f79bf46d4dda845b4471465"><strong>Pérez, Nicolás</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?d0fb85b9b22f92ef4a70add4ffe11e45"><strong>Pereyra, Josefina</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Sanabria, Yasmina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Blacque, Olivier</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?5c1ca4d55a5933a1752b3fc23d7cad09c4e5df59004aa474d3d272c7b6b5d79efe1957de15b2f0c75050b8d88b94dc89f36f3a8703836670d171bb4291eb6134"><strong>Machado, Ignacio</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?2d35158f014abe22856568516f465398b41f31af2f7026a5bd8f2a7471112a97b1095db07aacaf024ad34d0e28008365ec7bd0755dce0607fa8620090913b6b9"><strong>Pérez-Díaz, Leticia</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?6bb5dcce3e2559101357796ca4a2b2d4c9ba6b3a978a0bd4c5dab0107081b73e1ff46dcf49a7de2b571ff7980c4a01789f09f1d7eac1b879a8553641f940b9a5"><strong>Gambino, Dinorah</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Journal of Inorganic Biochemistry, v. 269, 2025. -- e112891]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2025]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Información sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislación uruguaya protege el derecho</strong> de autor sobre toda creación literaria, científica o artística, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeción a lo establecido por el derecho común y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptación de las siguientes condiciones de uso: Este documento es únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilización o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[14 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Inglés]]></dcterms:language>
    <dcterms:type><![CDATA[Artículo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.1016/j.jinorgbio.2025.112891]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6588">
    <dcterms:title><![CDATA[Do bioactive 8-hydroxyquinolines oxidovanadium(IV) and (V) complexes inhibit the growth of M. smegmatis?]]></dcterms:title>
    <dcterms:subject><![CDATA[<div class="element-text">MYCOBACTERIUM SMEGMATIS</div>]]></dcterms:subject>
    <dcterms:subject><![CDATA[OXIDOVANADIO]]></dcterms:subject>
    <dcterms:subject><![CDATA[VANADIO]]></dcterms:subject>
    <dcterms:subject><![CDATA[ESPECIACION]]></dcterms:subject>
    <dcterms:subject><![CDATA[COMPLEJOS DE COORDINACION]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2022]]></dcterms:subject>
    <dcterms:abstract><![CDATA[The antiproliferative effects of four series of VIVO- and VVO-based compounds containing 8-hydroxyquinoline ligands on the bacterium Mycolicibacterium smegmatis (M. smeg) were investigated. The effects on M. smeg were compared to the antiproliferative effects on the protozoan parasite Trypanosoma cruzi (T. cruzi), the causative agent for Chagas disease. In this study, we investigate the speciation of these compounds under physiological conditions as well as the antiproliferative effects on the bacterium M. smeg. We find that the complexes are more stable the less H2O is present, and that the stability increases in lipid-like environments.<br />Only one heteroleptic complex and two homoleptic complexes were found to show similar antiproliferative effects on M. smeg as reported for T. cruzi so the responses generally observed by M.smeg. is less than observed by the pathogen. In summary, we find that M. smeg is more sensitive to the detailed structure of the V-complex but overall these complexes are less effective against M. smeg compared to T. cruzi.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[Scalese, Gonzalo]]></dcterms:creator>
    <dcterms:creator><![CDATA[Arhouma, Zeyad]]></dcterms:creator>
    <dcterms:creator><![CDATA[Kostenkova, Kateryna]]></dcterms:creator>
    <dcterms:creator><![CDATA[P&eacute;rez-D&iacute;az, Leticia]]></dcterms:creator>
    <dcterms:creator><![CDATA[C. Crick, Dean]]></dcterms:creator>
    <dcterms:creator><![CDATA[Gambino, Dinorah]]></dcterms:creator>
    <dcterms:creator><![CDATA[Crans, Debbie C.]]></dcterms:creator>
    <dcterms:source><![CDATA[Journal of Inorganic Biochemistry, v.237, 2022. -- e111984]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2022]]></dcterms:date>
    <dcterms:rights><![CDATA[<div class="element-text">
<p dir="ltr"><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p dir="ltr">(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p dir="ltr"><strong>La legislaci&oacute;n uruguaya protege el derecho de autor</strong>&nbsp;sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<span id="docs-internal-guid-9d2103f7-7fff-c813-00c7-2528fd4891ff"><strong>ADVERTENCIA:</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</span></div>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[15 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:identifier><![CDATA[10.1016/j.jinorgbio.2022.111984]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/4803">
    <dcterms:title><![CDATA[<strong>Evaluation of cellular uptake, cytotoxicity and cellular ultrastructural effects of heteroleptic oxidovanadium(IV) complexes of salicylaldimines and polypyridyl ligands</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ANTINEOPLASICOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[OXIDOVANADIO]]></dcterms:subject>
    <dcterms:subject><![CDATA[COMPLEJOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2017]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Searching for prospective vanadium-based drugs for cancer treatment, a new series of structurally related [VIVO(L &minus; 2H)(NN)] compounds (1&ndash;8) was developed. They include a double deprotonated salicylaldimine Schiff base ligand (L-2H) and different NN-polypyridyl co-ligands having DNA intercalating capacity. Compounds were characterized in solid state and in solution. EPR spectroscopy suggests that the NN ligands act as bidentate and bind through both nitrogen donor atoms in an axial-equatorial mode. The cytotoxicity was evaluated in human tumoral cells (ovarian A2780, breast MCF7, prostate PC3). The cytotoxic activity was dependent on type of cell and incubation time. At 24 h PC3 cells presented low sensitivity, but at 72 h all complexes showed high cytotoxic activity in all cells. Human kidney HEK293 and ovarian cisplatin resistant A2780cisR cells were also included to evaluate selectivity towards cancer cells and potency to overcome cisplatin resistance, respectively. Most complexes showed no detectable interaction with plasmid DNA, except 2 and 7 which depicted low ability to induce single strand breaks in supercoiled DNA. Based on the overall cytotoxic profile, complexes with 2,2&acute;-bipyridine and 1,10-phenanthroline ligands (1 and 2) were selected for further studies, which consisted on cellular distribution and ultrastructural analyses. In the A2780 cells both depicted different distribution profiles; the former accumulates mostly at the membrane and the latter in the cytoskeleton. Morphology of treated cells showed nuclear atypia and membrane alterations, more severe for 1. Complexes induce different cell death pathways, predominantly necrosis for 1 and apoptosis for 2. Complexes alternative mode of cell death motivates the possibility for further developments.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Scalese, Gonzalo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Correia, Isabel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Benitez, Julio</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Rostan, Sergio.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Marques, Fernanda</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mendes, Filipa</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Matos, Ant&oacute;nio Pedro</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Costa Pessoa, Jo&atilde;o</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=2ff5755f42707a83e7aea75299e5667c" target="_self"><strong>Gambino, Dinorah.</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Journal of Inorganic Biochemistry v. 166, 2017. -- p. 162-172]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2017]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1016/j.jinorgbio.2016.11.010]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3702">
    <dcterms:title><![CDATA[<strong>Exploring Oxidovanadium(IV) Complexes as YopH Inhibitors : Mechanism of Action and Modeling Studies</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[OXIDOVANADIO]]></dcterms:subject>
    <dcterms:subject><![CDATA[CATIONES]]></dcterms:subject>
    <dcterms:subject><![CDATA[HIDROGENO]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2015]]></dcterms:subject>
    <dcterms:creator><![CDATA[<strong>Alves Martins, Priscila</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mattia Mori, Louise D.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Chiaradia-Delatorre, Angela</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Menegatti, C. O.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mascarello, Alessandra</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Botta, Bruno</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ben&iacute;tez, Julio</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=2ff5755f42707a83e7aea75299e5667c" target="_blank"><strong>Gambino, Dinorah</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Terenzi, Hern&aacute;n</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[ACS Medicinal Chemistry Letters, 6 (10), pp. 1035-1040 v. 6, no. 10, 2015. -- p. 1035-1040]]></dcterms:source>
    <dcterms:publisher><![CDATA[ACS]]></dcterms:publisher>
    <dcterms:date><![CDATA[2015]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong><br /> <br /> (Por favor lea este aviso antes de abrir los documentos u objetos)<br /> <br /> <strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes<br /> <br /> (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)<br /> <br /> <strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1021/acsmedchemlett.5b00267]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/677">
    <dcterms:title><![CDATA[<strong>A new series of heteroleptic oxidovanadium(iv) compounds with phenanthroline-derived co-ligands: selective Trypanosoma cruzi growth inhibitors</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ANTIHELMINTICOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[TRIPANOSOMIASIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTITRIPANOSOSMAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[OXIDOVANADIO]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2013]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Searching for prospective metal-based drugs for the treatment of Chagas disease, a new series of ten mixed-ligand oxidovanadium(IV) complexes, [VIVO(L-2H)(NN)], where L is a tridentate salicylaldehyde semicarbazone derivative (L1&ndash;L5) and NN is either 5-amine-1,10-phenanthroline (aminophen) or 5,6-epoxy-5,6-dihydro-1,10-phenanthroline (epoxyphen), were synthesized. The compounds were characterized in the solid state and in solution. EPR spectroscopy suggests that the NN ligands act as bidentate through both nitrogen donor atoms in an axial&ndash;equatorial mode. The stability of the complexes in solution was investigated by EPR and 51V-nuclear magnetic resonance spectroscopies. The complexes were evaluated in vitro for their activities against Trypanosoma cruzi (T. cruzi), the parasite responsible for the disease, and their selectivity was analyzed using J-774 murine macrophages, as a mammalian model. All the complexes are more active than both the reference drug Nifurtimox and the previously reported [VIVO(L-2H)(NN)] complexes. In general they are more active than the corresponding free NN ligands. Complexation led to highly increased selectivities towards the parasite. In addition, the lipophilicity of the compounds was determined and correlated with the observed activity in order to perform a QSAR (quantitative structure&ndash;activity relationship) study. A clear quadratic correlation is found. This study also confirms the influence of the structure of the co-ligand on the anti-T. cruzi effect. To get insight into the mechanism of action of the compounds, the changes in biochemical pathways promoted by two of the most active and most selective complexes are studied by analyzing a few of the parasite excreted metabolites by 1H NMR spectroscopy. The combined information suggests that the mitochondrion could be a target for these complexes. Furthermore, DNA was preliminarily evaluated as a potential target by using atomic force microscopy (AFM), which showed that the complexes display an ability to interact with this biomolecule.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Fern&aacute;ndez, Mariana</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Varela, Javier</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Correia, Isabel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Birriel, Estefania</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curr&iacute;culum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=94a8ff70d2730e3c95703f810fd79d7c" target="_blank"><strong>Castiglioni, Jorge</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Moreno, Virtudes</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Costa Pessoa, Joao</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Cerecetto, Hugo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gonz&aacute;lez, Mercedes</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curr&iacute;culum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=2ff5755f42707a83e7aea75299e5667c" target="_blank"><strong>Gambino, Dinorah</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Dalton Transactions 2013. Disponible Online]]></dcterms:source>
    <dcterms:publisher><![CDATA[Royal Society of Chemistry]]></dcterms:publisher>
    <dcterms:date><![CDATA[2013]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
<p>&nbsp;</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1039/C3DT50512J]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/671">
    <dcterms:title><![CDATA[<strong>Searching for vanadium-based prospective agents against Trypanosoma cruzi: oxidovanadium(IV) compounds with phenanthroline derivatives as ligands</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ANTITRIPANOSOMAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[TRIPANOSOMA CRUZI]]></dcterms:subject>
    <dcterms:subject><![CDATA[OXIDOVANADIO]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2013]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Searching for new promising metal-based drugs for the treatment of parasitic diseases against Trypanosoma cruzi, three related oxidovanadium(IV) complexes, [VIVO(SO4)(H2O)2(NN)], with the phenanthroline derivatives (NN) 1,2,5thiadiazolo[3,4-f]1,10phenanthroline (tdzp), 1,10-phenanthroline-5, 6-dione (phendione), and 5,6-epoxy-5,6-dihydro-1,10-phenanthroline (epoxyphen) are synthesized, characterized, and evaluated in vitro as anti-T. cruzi agents. The compounds are characterized in the solid state and in solution by elemental analysis, electrospray ionization mass spectrometry (ESI-MS), conductimetric measurements, and infrared (FTIR), UV/Vis, and electronic paramagnetic resonance (EPR) spectroscopy. EPR spectroscopy suggests that the ligands act as bidentate, binding through both nitrogen donor atoms in an axial-equatorial mode. DFT calculations corroborate the structural assignments. The stability of the complexes in solution is evaluated by EPR and 51V- NMR spectroscopy and all complexes show reasonable stability. The anti-T. cruzi activity of the complexes was tested by measuring the growth inhibitory effect on the epimastigote life cycle form of the parasite (Dm28c strain). All complexes show IC50 values in the micromolar range against T. cruzi and display activities of the same order of that of Nifurtimox, but lower than that of the previously reported analogue [VIVO(SO4)(H2O)2(dppz)] (dppz = dipyrido[3, 2-a:2&prime;,3&prime;-c]phenazine). Furthermore, DNA was evaluated as a potential target by using atomic force microscopy (AFM), showing that the complexes display ability to interact with this biomolecule.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Ben&iacute;tez, Julio</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Correia, Isabel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Becco, Lorena</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fern&aacute;ndez, Mariana</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Garat, Beatriz</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gallardo, Hugo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Conte, Gilmar</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Kuznetsov, Maxim L.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Neves, Ademir</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Moreno, Virtudes</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Costa Pessoa, Jo&atilde;o</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curr&iacute;culum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=2ff5755f42707a83e7aea75299e5667c" target="_blank"><strong>Gambino, Dinorah</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Zeitschrift f&uuml;r anorganische und allgemeine Chemie v. 639, no. 8-9, 2013. -- p. 1417-1425]]></dcterms:source>
    <dcterms:publisher><![CDATA[Wiley]]></dcterms:publisher>
    <dcterms:date><![CDATA[2013]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
<p>&nbsp;</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1002/zaac.201300057]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/610">
    <dcterms:title><![CDATA[<strong>New oxidovanadium(IV) N-acylhydrazone complexes :&nbsp; Promising antileishmanial and antitrypanosomal agents</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[LEISHMANIASIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTITRIPANOSOMAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ENFERMEDAD DE CHAGAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[OXIDOVANADIO]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2013]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Searchingfor newpromisingmetal-based hits against Trypanosoma cruzi andLeishmaniaparasites,two related oxidovanadium(IV) N-acylhydrazone complexes, [VIVO(LASSBio1064-2H)(H2O)], 1, and [VIVO(LASSBio1064- 2H)(phen)]$(H2O), 2, where LASSBio1064&frac14; (E)-N0-(2-hydroxybenzylidene-4-chlorobenzohydrazide and phen &frac14; 1,10-phenanthroline, were synthesized and characterized in the solid state and in solution by elemental analysis, conductimetric measurements and ESI-MS, FTIR, EPR and 51V NMR spectroscopies and were evaluated on T. cruzi and Leishmania major. In addition, their unspecific cytotoxicity was tested against murine macrophages. Furthermore, to provide insight into the possible mechanism of its antiparasitic action, [VO(LASSbio1064-2H)(phen)].(H2O)was tested for its DNA interaction ability on plasmid DNA by atomic force microscopy (AFM) and on CT DNA by using DNAviscosity measurements and fluorescence spectroscopy. Both complexeswere active in vitro against the epimastigote formof T. cruzi (Tulahuen 2 strain) showing IC50 values of the same orderor significantly lower thanthat of the reference trypanosomicidal drug Nifurtimox.However, only the mixed-ligand oxidovanadium(IV) complex 2,which includes phen in its coordination sphere, showed activity on L. major promastigotes with a IC50 value of 22.1  0.6 mM. The compounds show low toxicity on mammalian cells (IC50 &gt; 100 mM). DNA interaction studies showed that the mixed-ligand complex is able to interact with this biomolecule probably through an intercalative mode, pointing out at DNA as a potential target in the parasite. The results suggest that [VIVO(LASSBio1064-2H)(phen)]$(H2O) may be a promising compound for further drug development stages]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Ben&iacute;tez, Julio</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Cavalcanti de Queiroz, Aline</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Correia, Isabel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Amaral Alvez, Marina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Alexandre-Moreira, Magna S.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Barreiro, Eliezer J.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Moreira Lima, Lidia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Varela, Javier</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gonz&aacute;lez, Mercedes</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Cerecetto, Hugo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Moreno, Virtudes</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Costa Pessoa, Jo&atilde;o</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curr&iacute;culum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=2ff5755f42707a83e7aea75299e5667c" target="_blank"><strong>Gambino, Dinorah</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[European Journal of Medicinal Chemistry v. 62C, no. 1, 2013. -- p. 20-27]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2013]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
<p>&nbsp;</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[http://dx.doi.org/10.1016/j.ejmech.2012.12.036]]></dcterms:identifier>
</rdf:Description></rdf:RDF>
